SS-31 for fatigue and energy: reading the trials past the marketing

Short answer: SS-31 for fatigue and energy has excellent human safety data and a genuinely interesting mitochondrial mechanism, but almost none of the human trials behind it measured fatigue or energy directly. If you are reading vendor copy that cites "475 patients" as proof it fixes tiredness, you are reading a safety number dressed up as an efficacy claim, and the difference matters.

I get asked about this compound constantly by clients who found it through a Long COVID forum or a biohacker channel, and the pitch is always the same: mitochondria make your energy, SS-31 fixes your mitochondria, therefore SS-31 fixes your energy. Each link in that chain is defensible on its own. The full chain has never been tested in a dedicated human trial.

What the trials actually measured

SS-31, sold under the brand name Forzinity after its 2025 FDA approval, has one of the cleanest human safety profiles of any peptide I cover. The original mechanistic groundwork goes back to Szeto's 2006 paper on the SS-peptide series binding cardiolipin, the phospholipid that holds your mitochondrial membrane together and keeps the electron transport chain from leaking electrons into reactive oxygen species. That leak-and-damage cycle is the plausible root of a lot of fatigue that shows up on paper as normal bloodwork.

The problem is what got tested afterward. The Barth syndrome extension trial ran patients at 40 mg/day for over three years and tracked muscle strength and heart function. The MELAS trial from Karaa and colleagues looked at a different mitochondrial disease population with its own endpoints. The macular degeneration and heart failure trials targeted eye and cardiac outcomes and came back null on their primary endpoints in those specific populations. None of these were fatigue trials. Pulling "energy" out of muscle-strength improvements in Barth syndrome is a reasonable inference, but it is still just an inference.

Where I see the fatigue argument actually built is in the animal and case-report layer. The PMC review of elamipretide's neuroprotective mechanisms covers reduced mitochondrial swelling and reduced neuroinflammation in TBI and Alzheimer's models, which is animal work, not human. It supports the mechanism story for why a fatigued brain running on damaged mitochondria might respond to SS-31, and it stops well short of showing that a fatigued human will.

Where the recent work adds something real

The most useful new piece of evidence I've seen for the energy angle is not about SS-31 alone. A 2026 paper on MOTS-c's independent ROS-reduction effect found that MOTS-c improves muscle mitochondrial efficiency and cuts reactive oxygen species through a separate pathway from the one SS-31 works on. That's still animal data, but it clarifies why people run the two together. SS-31 stabilizes the membrane so fewer electrons leak in the first place. MOTS-c improves how efficiently the mitochondria you already have convert fuel into ATP and pushes your cells to build more mitochondrial capacity. Different jobs, same organelle, and stacking them makes more mechanistic sense than either compound alone for a straightforward fatigue complaint.

I want to walk through the anticardiolipin antibody angle too, because it is the most interesting unproven idea in this space right now. Several small studies have found elevated antibodies against cardiolipin in chronic fatigue populations, and the theory is that these antibodies attack cardiolipin that has leaked outside a stressed mitochondrion, worsening the same damage cycle from the outside. If that theory holds, it would explain why some patients with entirely normal standard labs still feel wrecked, and why they might respond to a peptide that shields cardiolipin. I find the theory compelling, and it has not been confirmed in a large trial, so I tell clients that clearly before they spend money chasing it.

If you want the deeper mechanism and dosing breakdown, I've laid out the full picture in the SS-31 encyclopedia entry. For a comparison of a different fatigue-focused compound that works through an entirely separate pathway, see the 5-Amino-1MQ fatigue and energy piece.

What I tell clients who want to try it anyway

The absence of a fatigue-specific trial doesn't mean skip it. It means you should know exactly what you're buying: a compound with an exceptional safety record, a well-supported mechanism for why it should help mitochondrial-driven fatigue, and human evidence that it works in specific disease populations that are not simply "tired all the time with normal labs." That's a reasonable bet for someone with lab-confirmed mitochondrial dysfunction, a Long COVID history, or a doctor who's ruled out the usual suspects. It's a weaker bet for someone in their late twenties who is just tired from a bad sleep schedule, because the animal data on younger subjects showed no benefit at all when mitochondria weren't already declining.

On dosing: the trials that generated the safety record used up to 40 mg/day subcutaneously. The real-world protocol most people actually run outside a Barth syndrome context is 5 to 10 mg/day, with some practitioners going to 10 mg/day for severe chronic fatigue presentations. I run mine in that range and adjust based on how a client's biomarkers move over a few months rather than following a fixed schedule someone else posted online.

Now the part my lawyer makes me say, and he's right to: The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

One process note people ask about constantly: normal handling like swirling a reconstituted vial does not damage this peptide. The things that actually degrade it are heat, light, time sitting in solution, and repeated freeze-thaw cycles, not gentle agitation. If you're new to reconstitution and storage generally, the aliquoting and freeze-thaw breakdown covers the real failure points.

Where this leaves the reader is a genuinely strong safety record, a well-mapped mechanism, human trials in adjacent mitochondrial diseases, and a fatigue-and-energy application that still rests on inference and case reports rather than its own dedicated study. Decide where you sit on that gap before you spend three months and a few hundred dollars a month finding out for yourself.